Lineage Cell Therapeutics, Inc.
LCTXStock
$1.17+22.00%52W
Market Cap$304.14M
P/E—
Div yield—
Beta1.50
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-42.79%
Price vs S&P 500 (4W)1.07%
VGM Score42.84
Market Capitalization$304.14M
Earnings Surprise History
Q1 26-0.03est. -0.02
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.08
4.07
4.08
4.08
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LCTXLineage Cell Therapeutics, Inc. | C | C | D | $1.17 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell replacement and cell/drug delivery therapies for degenerative diseases. Key pipeline candidates include OpRegen for age-related macular degeneration, OPC1 for spinal cord injuries, VAC2 for non-small cell lung cancer, and cell therapies for hearing and vision loss.